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P R E F A C E 
Nitrogen heterocylic molecules are found extensively 
in biological systems, and have been chosen by nature to 
carry out many fundamental reactions of living organisms. 
Nucleosides, the nitrogen glycosides of purines and 
pyrimidines and their phosphate esters, known as nucleotides 
are vital components of all living cells and are intimately 
involved in many biological processes-such as protein 
synthesis, storage and transformation of genetic information, 
oxidation-reduction and electron transport processes. Some 
of the well known nucleoside antibiotics Are puromycin, 
nebularine, formycin and spongosine. 
Chemical modifications of naturally occurring nucleosides 
have provided many useful drugs for the treatment of a number 
of diseases. 
In the thesis the synthetic analogues of biologically 
active nucleosides and their biological evaluation is 
described. It is divided into three chapters: 
The first chapter is introductory and deals with their 
spectral properties. 
In the second chapter the synthesis of 4,6-disubstituted-
1-H-tetrahydrofuranyl pyrazolo L3,4-dJ pyrimidine based on 
c\o 
6-amino-2-propoxy-9-cyclohexyl adenine and the evaluation 
of the compounds for antiviral and antiallergic activities 
is described. 
The third chapter deals with the synthesis of 4,6-
disubstituted pyrazolo V3,4-d]l pyrimidine ribosides, a 
spongosine analogue. The biological screening data of the 
compounds synthesised is also given in this chapter. 
A B B R E V I A T I O N S 
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CmPTER-1 
1.0 REVIEW OF LITERATURE 
1.1 Introduction 
Nucleosides, the nitrogen glycosides of purine and 
pyrimidines and their phosphate esters, known as nucleotides 
could be broadly classified into two classes; 
(1) N-Nucleoside and (2) C-Nucleoside 
In N-nuclebside {!_) sugar moiety is attached to the 
heterocycle ring by a C-N bond, whereas in C-nucleoside (2_) 
the two moieties are linked through C-C bond. N-nucleosides 
are vital components of all living cells and are intimately 
Ov r-OH 
\ 
/ 
n 
OH HO 
1 \ 
involved in several metabolic processes , such as RNA, .DNA 
and protein syntheses and also regulate many enzymatic 
reactions in cell. Some of the common nucleosides which 
are consituents of nucleic acid are given in Fig. 1. 
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Fig. 1: Constituents of nucleic acid 
1.2 Nucleoside antibiotics 
Several nucleoside^exhibiting antibiotic activity have 
been isolated from micro-ojrganismsr some of these have been 
2-5 found very effective as anticancer and antiviral agents . 
Nucleoside antibiotic can be broadly divided into three 
groups: 
CD The nucleosides where the heterocyclic moiety is 
normal purine or pyrimidine base but the sugar 
moiety is modified. Examples of this class of 
nucleosides are _ Psicofuranine {8} and 
3'-amino-3'-deoxyadenosine {9). 
SJH, 
oH 
3'-amino-3'-deoxyaderiosine 
9 
(2) The nucleoside,where the heterocyclic moiety is 
modified and sug^r is ribose or deoxy ribose,for 
example - Spongosine^ (IjO), f ormycin^ (Ij^), 
Toyocamycin (12_), nebularine-"--*- (1_3), 5'-deoxy-5-
iodotubercidin (14_), cadeguamycin"'-^"-^^ (1^), 
15 16 bredenin (16), showdomycin (17) and pyrazomycin 
(18) . 
17 
^^z r4H, 
J^^/^H^ 
O^r-OH 
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(3) Nucleoside-j in which both heterocycle and sugar 
moiety are modified. Examples of this group 
ere - Puro:i:iycin (!_?_) and amicetin ~ (20_) . 
HC 
Puromycin 
19 
0 O 
>1 \l W O C - C H - C - N W - / "^  
M H 
•CCH-) 
Amicetin 
20 
6 
1.3 Synthetic nucleosides of biological interest 
Several nucleosides have been synthesized in recent 
years, and many of these have shovm significant anticancer, 
antiviral and antiparasitic activities. Some of the 
synthetic nucleosides which are in clinical use are given 
below. 
21 
E-Bromovinyl deoxyur id ine (BVDU) (21) 
0 iii 
The above pyrimidine nucleoside 21_ has antiviral activity 
against pseudorabies virus, bovine herpes virus (Type-1), 
simian varicella virus and herpes virus saimiri. The 
nucleoside is phosphorylated by the virus coded thymidine 
kinase to the diphosphate derivative, and further by 
cellular thymidine kinase to its 5'-triphosphate form. The 
triphosphate is incorporated into viral DNA but not with 
host DNA and is, therefore, selective for viral DNA. 
FIAC 1^1- (2-deoxy-2-f luoro- 3-D-arabvnofuranosyl) - 5 - i o d o -
cy toF ine l (22) 22 
^'M. 
\Cf°' 
OH 
It is a pyrimidine nucleoside with modified sugar as well 
as base and is competitive substrate for viral enzymes, 
and show antiviral activity against viral zoster (VZV), 
herpes simplex virus (HSV-1 and HSV-2), cytomegalo virus 
and Epstein-Barr virus iri vitro and in animal model systems, 
NH, 
OH 
Ribavirin (23) Q 
HO OM 
23. 
Ribavirin (23) is effective against three different groups 
23 24 25 
of diseases: herpes infections , hepatitis and influenza 
infections. It is structurally related to guanosine and 
acts by inhibiting an enzyme necessary ^ for the biosynthesis 
8 
of guanine base. In the case of influenza, ribavirin seems 
to specifically inhibit the synthesis of influenza viral 
r-roteins. 
6-Thiociuanine and 6-mercaptopurine (24, 25) 
24 25 
Some commonly used purine antagonists in cancer chemo-
therapy are: 6-thioguanine (24) and 6-mercaptopurine (25) . 
6-Thioguanine are believed to act by incorporation of their 
nucleotide into DNA. In contrast 5-mercaptopurine blocks 
the first enzyme of purine biosynthesis pathway i.e. phos-
phoribosyl pyrophosphate amido transferase. This suppresses 
de novo purine synthesis as ribosylamine-5-phosphate can no 
longer be synthesized from glutamine and 5-phosphoribosyl-1-
pyrophosphate (PRPP). 
Vidarabine (Ara-A) (26) 
?6 
9 
Ara-A (26) is used as antiviral agent and is active against 
27 28 
most D1\A and some RKA viruses ' . Ara-A is efficacious 
in the trectment of disseminated herpes zoster and herpes 
sip])3ex encephalitis. When Ara-A is taken by the cell 
using uridine-thymidine transport mechanism, it has two 
major fates, first it is phosphotylate to "produce Ara-ATP 
29 
end the other conversion by deamination to Ara-H . Ara-ATP 
inhibits reactions required for cellular and viral DNA 
synthesis. In addition to cellular inhibition, Ara-A is 
30-31 
also incorporated into the DNA" 
33 Acyclovir (ACV, acycloguanosine) (27) 
OH 
H, 
27 
Acyclovir (22.) is a guanine derivative with an acyclic side 
chain and shows selective antiviral activity against herpes 
simplex virus (type 1 & 2). The acyclic chain of acyclovir 
is metabolized to its monophosphate derivative by the virus 
coded thymidine kinase to which the drug binds much more 
efficiently than to the cellular thymidine kinase. It is 
10 
used clinically for tropical application in herpes kerato-
conjunctivitis ana systeiriatically in the therapy of genital 
32 
ncrpes mfecrions and herpes zos ter . 
£• Il.§'•^K°9M:-J:A'^x^',.^z9'.^^'??.S'^.^^^PP?-^P ^^ -"^  " - d e a z a g u a n o s i n e 
p h o s c h c t e (28, 29 & 30) 
H 
O ^ r - O H 
OH 
29 
3-Deazaguanine (^ S^ ), shows antitumor activity. It inhibits 
34 DNA and protein synthesis . It also inhibits the proli-
35 feration of HL-60 cells , due to inhibition of IMP 
dehydrogenase and a lowering of guanine nucleotide pools 36-37 
The nucleosides of 3-deazaguanine (2'-deoxy-3-deazaguanosine, 
38 29) is more potent than 3-deazaguanine. The nucleotide 
11 
3-deazaguanosine, 3'-5' cyclic monophosphate (30) shows 
38 the greatest activity . It is presumed that 30_ may be 
able to cross the tumour membrane intact and then be 
converted to S-deaza G MP by C-GMP phosphodiesterase within 
39 the cell. Further 3-deaza GMP is a good inhibitor of 
IMP dehydrogenase. 
8-Azainosine (31) 
OH 
The compound is commonly used as anticancer drug. In the 
presence of adenosine kinase, 31 is converted to 8-azainosine-
40 
monophosphate (8-Aza IMP) which is powerful inhibitor of 
PRPP-amidotransferase, the first enzyme of purine biosynthesis 
pathway. 
Sanqivamycin and thiosangivamycin (32, 33) 
Thio-sangivamycin (33) is an analogue of sangivamycin 
(32) antibiotics and shows antitumour activity. Sangivamycin 
41 inhibits RNA synthesis, while thiosangivamycin inhibited 
12 
RNA synthesis and impaired DNA synthesis. Thiosangivamycin 
DVA 
H O OH 
33 
significantly inhibited mathylation of ribosomal RNA. Due 
41 to these greater metabolic activity , 33_ is more potent 
than sangivamycin itself. 
1.4 Physical methods for characterization of nucleosides 
Various methods used in the characterization of 
nucleosides are UV, NMR and mass spectrometry. UV spectro-
scopy is used to assign the position of glycosylation 
whereas NMR is used to find out the configuration of the 
glycosidic linkage. 
1.4.1 UV-Spectrvun of nucleoside 
In UV-spectrum of unsubstituted purine, generally two 
bands - one at 263 and another at 188 nm appears, which are 
13 
42 
designated as 'X' and 'Y' bands respectively. Manson has 
suggested that the absorption peak at 253 {X band) occurs 
due to a longitudinal polarization (i.e. betv/een C-2 and 
C-8) of the purine nucleus and is analogous to the peak 
at 255 riin of benzene. The 188 nm absorption band (Y) is 
considered to arise due to the transverse polarization. The 
change in wavelength of 'X' band vary according to the 
position of substituent in the purine. In general the 
bathochromic shift increases in the order of position of the 
substituent at 6<8<2 and that of hyperchromic effect 2<6<8. 
In both purine and pyrimidine nucleosides, there is 
no remarkable difference in UV-spectrum by replacement of 
the alkyl group with sugar moiety. The hydroxy group 
absorption can be found below 200 nm. The ionization of 
hydroxyl group can be detected above pH 11, although it 
has so far been little sought. Adenosine (3_1) has UV-
spectrum similar to 9-methyladenine (3_5^) and differ than that 
of 7-, 1- or 3-methyladenine. 
Ov ,-c?H 
Co 
H6 6H 
Xmax 190 and 260 im Amax 260 nm 
34 35 
14 
1.4.2 ijMR-spectrum of nucleosides 
NMR-spectroscpy i s an invaluable tool, in the d e t e r -
mination of anomeric configuration of the nucleosides. I t 
43 
has been observed tha t the dihedral angle between neigh-
bouring hydrogen atoms in (a-D-ribofuranosyl der iva t ives) 
(36) vary from 0-45° whereas in case of ( ^D-ribofuranosyl 
derivat ive) (37) vary from 75-120 . The coupling constant 
44 as predicted by Karplus equation i s expected between 4.3 
to 8.0 Hz for the a-D-configuration and 0.3-8.0 Hz for the 
&-D-configuration. 
HO low 
36 37 
Thus' coupling constant for g-ribosides is less than 
OC-ribosides till the J^4.3 Hz. However, the ambiguity 
between a and fr-isomers can be resolved by applying 
45 Imbach's rule . The a and g nucleosides are converted to 
the corresponding isopropylidine derivatives and the chemical 
46-48 
shif t difference" (A 6) between methyl resonance of 2 ' , 3 ' 
15 
isopropylidine acetals is diagnostic for anomeric deter-
mination. According to Imbach's observation in a-isomers, 
the A6 is generaliy less than 0.15 ppm while B-isomers have 
A6> 0.15 ppm. The reason for this.difference in a and 3 
isomers has been explained as follows. 
^ CH3^«*^0> 
a-anomer 
38 
CH^ «^**> 
Bflse 
3-anomer 
39 
If we suppose the methyl of isopropylidine acetal, the 
exo methyl group as a and the endo methyl group as y as 
shown in Fig. (38_) and {39), it is noteworthy that the 
y-methyl group in 3-nucleoside, resonates downfield as 
compared to the a-methyl group due to the more deshielding 
effect of bicyclic ring whereas in a nucleoside, both the 
methyl groups experience deshielding effect of heterocyclic 
ring causing little difference in their chemical shift. 
16 
1.4.3 Mass-spectrum of nucleosides 
The mass fragmentation pattern of heterocyclic moiety 
of the nucleoside is almost identical to that of the parent 
base. The fragmentation pattern of the sugar moiety,however, 
provides considerable information. The fragmentation pattern 
of adenosine is given below. 
viU 
OH 
WO OH 
34 
MH 
- new 
> 
MHr 1 + 
r f 
WO OH 
44 
-•WWQ.CN ..-^ 
W 
> 
40 m/e 135 41 m/e 108 42 m/e 66 
The purine part of adenosine (34) can be easily recognised 
by an intense peak at m/e 135 (B + H), £0^ , having the same 
17 
mass to charge ratio as the free base or base plus two 
hydrogen atom (B + 2H). The one hydrogen atom from the 
hydroxy group of sugar moiety (44) is transferred to the 
heterocyclic moiety and C-l-N (glycoside) bond is cleaved. 
The peak at m/e (B + 2H) is more prominent in the mass 
spectrum of D-ribosyl than the 2-deoxy-D-ribosyl derivatives. 
Further, the (B + 2H) peak m pyrimidine nucleoside is more 
prominent than purine nucleosides. The next fragmentatic5n 
in the purine system is that of pyrimidine ring. One 
molecule of HCN is lost from scission of the C-2-N-3 bond 
and finally H^N-CN is lost giving rise to the peak at m/e 
66 of (£2). 
In the case of nucleoside a strong peak at m/e 133 is 
49 50 
characteristic of D-ribose (44), while in 2-^eoxy ribose ' 
it occurs at m/e 117. The intensity of this peak is lower 
in purine nucleosides than in pyrimidine nucleosides. 
Fragments of D-ribose are generally less abundant than 
the corresponding 2-deoxy-D-ribose fragment. There are 
marked variations in the intensities of certain peaks in 
the mass spectrum of epimers, however, the fragments formed 
are the same. Commonly, a peak is found at m/e correspond-
50 ing to 30 mass unit higher than the base, (B + 30) which 
can be explained by the formation of (43). 
18 
uv\ 
m/e (B+30) 
34 43 
ChAPTER-2 
2 . 0 SYNTHESES OF 6-^ErHOXY/METHYLTHIO-4-N-SUBSTITUTED-I-
hl-TETRAHYDROFURANYL PYRAZOLO {_3,4-d~j PYRIMIDINE AND 
ThEIR BIOLOGICAL ACTIVITIES 
19 
2 . 1 I n t r o d u c t i o n 
S e v e r a l v a r i e t i e s of n u c l e o s i d e s have been s y n t h e s i z e d 
i n r e c e n t y e a r s . Some of t h e s e n u c l e o s i d e s have shown 
s i g n i f i c a n t a n t i c a n c e r , a n t i p a r a s i t i c and a n t i v i r a l a c t i -
v i t i e s . A few of t h e s e a r e be ing used a s d r u g s . One of 
t h e d rawbacks of t h e b i o l o g i c a l l y a c t i v e n u c l e o s i d e s i s 
t h a t t h e y a r e n o t g e n e r a l l y s p e c i f i c t o t h e i n f e c t e d c e l l s . 
51 F l b r a p h u r ( 5 - f l u o r o - l - t e t r a h y d r o - f u r y l - u r a c i l ) , ( 4 5 ) , 
33 9 - ( h y d r o x y e t h o x y - m e t h y l ) g u a n i n e (46) , 9 - c y c l o h e x y l - 6 -
52 p r o p o x y a d e n i n e C ^ ) , a r e v e r y a c t i v e compounds which a r e 
s p e c i f i c t o t h e i n f e c t e d c e l l s . These compounds (45-47) 
a r e no t t r u e n u c l e o s i d e s . A l t h o u g h t h e h e t e r o c y c l i c m o i e t y 
i n t h e s e compound i s t h e same a s p r e s e n t i n t h e n u c l e o s i d e , 
however, t h e a g l y c o n p a r t i s n o t t h e u s u a l s u g a r . 
0 45 h\VA^ 
46 47 
20 
The tetrahydrofuryl, cyclohexyl, hydroxy ethoxymethyl moie-
9 
ties attached at position N in these compounds due to 
their hydrophilic nature may be facilitating the transport 
of these molecules across the cell membrane. Inside the 
cell these compounds might be converted into riboside by the 
action of ribofuranosyl transferase and to nucleosides. 
2.2 Present Work 
Since the attachment of tetrahydrofuranyl moiety to 
uracil moiety makes the molecule more lypophilic and hence 
become more effective. It VBS thought, worthwhile, to 
attach this moiety to various pyrazolo r3,4-d'] pyrimidines, 
The syntheses and biological activities of 4,6-dimethyl-
thio-1-tetrahydrofuranyl-pyrazolo (^ 3,4-^ ]] pyrimidine (48), 
4-alkylv-amino-6-methylthio-1-tetrahydrofuranyl pyrazolo 
[3,4-_d'] pyrimidine (£9_) and 4-alkylamino-6-methoxy-l-
tetrahydrofuranyl pyrazolo [3,4-di'] pyrimidine (5£) are 
reported in this chapter. 
t^m^ 
V^HR. 
QMi i r> 
C) 
0^9"^ 
48 49 50 
21 
2.3 Synthesis of 4, 6-dimethylthio-pyrazolo ]^, 4-d]jpyrimidine 
(57) (Scheme-1) 
4,6-dimethylthiopyrazolo r3,4-d| pyrimidine (57) needed 
for condensation reaction was synthesized by the procedure of 
53 Taylor et_ al. 
Malononitrile (51) was condensed with triethyl ortho-
54 formate (52) to afford ethoxymethylene malononitrile (5 3). 
Treatment of 53_ with hydrazine hydrate gave 5-amino-4-cyano-
55 pyrazole (^ ) . The reaction of 5^ with carbon disulphide in 
pyridine, followed by acid-base treatment, gave pyrazolo 
[3,4-^1 pyrimidine-4,6-dithione (56) in quantitative yield. 
Compound 55_ with methyliodide in presence of sodium hydroxide 
yielded 57_ in good yield. 
2.4 Synthesis of 4-alkylamino-6-methylthio-l-H^-tetrahydro-
furanyl pyrazolo ["3, 4^dJ pyrimidine (60-67) (Scheme-2) 
The reaction of 4,6-dimethylthiopyrazolo 3, 4-dJpyrimidine 
(57) with 2,3-dihydrofuran (58) in presence of £-toluene 
sulphonic acid and dry ethylacetate furnished the compound 
(59). Treatment of 5^ with various amines gave 4-N-substituted 
derivatives (60-67). The substituent at C-4 in pyrazolo 
I 3,4-d7pyrimidine system is more reactive as compared to C-6 
substituent towards nucleophilic substitution reaction because 
of the electrostatic repulsion of the nucleophile with lone 
pairs of electrons on two nitrogen atoms at C-6 substituent. 
Cstsl 
51 52 
CO 
22 
I 
53 
54 
Clin 
55 
Cw) W^ 
&CH3, 
56_ 
Reagen t s ( i ) {CH3CO)20 
( i i ) NH2NH2-H2O 
( i i i ) C S 2 / p y r i d i n e 
( iv) HCl/NaOH 
(v) CH3l/NaOH 
57 
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76. 
22 
78. 
X 
-NH^ 
-NHCH 
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6 3 , 7 1 , 79 
M' 21, 
65_, 73_, 
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-NH CH2CH2 
- N N CH-5 
OCH-
OCH. 
6"5 
24 
SCV43 
cu ^ S A N ^ V 
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CV^ O 
^ 3 
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76-83 84 
Scheme-2 
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2.5 Synthesis of 4-alkylamino-6-inethoxy-l-H-tetrahydro-
furanylpyrazolo []3,4-_d^  pyrimidine (Schenie-2) 
In order to prepare above compounds, the C-6 substituent 
in compounds (60-67) was converted to better leaving group. 
fhus, the reaction of compounds( 60-67iwith m-chloroperbenzoic 
acid in CH^Cl- gave corresponding sulphones (67-75). Treatment 
2. 2. ~ ~ 
of 67-75 with sodium methoxide in methanol gave the required 
compounds (76-83). 
2.6 Position of furanyl moiety in 4,6-dimethylthio-l-H-
tetrahydrofuranyl pyrazolo[^3, 4-^^ pyrimidine (59) 
In the synthesis of title compound the furanyl moiety 
may get attached either at N-1 or N-2 of the pyrazole ring 
in pyrazolo{]3, 4-^ J pyrimidine system. UV spectroscopic 
determination of the compounds obtained suggested that the 
furanyl moiety in 59_ is attached at N-1. 
56 
Robins and Cheng have prepared N-1 and N-2 substi-
tuted pyrazolo r3,4-dT pyrimidine by an unambiguous method, 
and it has been shown that replacement of sugar with alkyl 
57 group does not affect the UV absorption . Further they 
concluded that the difference in the UV absorption of N-1 
and N-2 substituted pyrazolo [^ 3,4-^ 3 pyrimidine (Table-1) 
is due to the fixed bond structure of N-2 substituted system. 
26 
which would be expected t o absorb a t longer wavelength 
58 
region 
Table-2 
Compound max(nm) References 
85 
86 
CVA^  
262 
268 
57 
5(S 
87 
<<^^>>: 
b 
269.5 i 56 
267 
88 294 56 
27 
59 Schmidt and coworker have further shown that 2-alkyl 
pyrazolo [^  3,4-d*] pyrimidine exhibit a bathochronic shift of 
15-25 nm compared to 1-alkyl derivatives. A comparison of 
UV absorption of 4, 6-dimethylthio-l-H-tetrahydrofuryl 
pyrazolo [[3, 4-dl pyrimidine (59) with 4-dimethylamino-l-
SC^i 
UV-absorption Amax 268 (nm) 
59 
methyl pyrazolo [^ 3, 4-^ *1 pyrimidine(85\ 4-dimethy 1 amino-1-
tetrahydrofuranyl pyrazolo ([_3,4-_d"| pyrimidine (87) and 
4-dimethylamino-2-methylpyrazolo r3, 4-_d'l pyrimidine (88>'have 
suggested that the reaction of 2,3-dihydrofuran with 4,6-
dimethylthiopyrazolo r3, 4-d^'l ^ rimidine has occurred at 
N-1. 
28 
2.7 Experimental Procedure 
Melting points were taken with Biichi capillary appa-
ratus (silicone bath) and were uncorrected. UV spectra 
were recorded on a Perkin Elmer-202 spectrophotometer 
(/max in nm), IR spectra on a Perkin Elmer-157 grating 
infracord ax cm" ). The PMR spectra were recorded on 
a Perkin Elmer 360L at 60 MHz (Chemical shift 6-scale). 
The compounds were routinely checked on silica gel plates 
and spots were located either under UV lamp, or by iodine 
vapours or spraying with Dragen Dorff's. 
4, 6-Dimethylthio-l-H-tetrahydrofuranylpyrazolo [3, 4-d"] 
pyrimidine (59) 
4, 6-Dimethylthiopyrazolo fs, 4-d. "1 pyrimidine (5 g, 
0.023 mol) in dry ethylacetate (100 ml) was added, 2,3-
dihydrofuran (4.5 ml, 0.063 mol) containing £-toluene 
sulphonic acid (0.15 g) and the mixture heated at 50 for 
3 hr. The reaction was cooled, washed with aq. K^CO-, 
water and dried (Na^SO.). Ethylacetate was removed 
in vacuo, and the residue crystallized from ether-hexane 
to give 5£ (yield 5.5 g, 80%), m.p. 107°. 
MS: m/e, 282 (M*^ ) 
UV:Amax (MeOH) 265 
PMR:(CDCl2): 2.1-1.8 (m, 4H, H-2' i H-3'), 2.5 (s, 3H, 
CH^-S-), 2.55 (s, 3H, S-CH^), 3.94-3.72 (m, 2H, H-4), 
29 
6.5 (m, IH, H-1'), 7.8 (s, IH, H-3) . 
C H^N^0S2 Found Calculated 
(MW = 282) c 
H 
N 
46 .48 
4 .78 
1 9 . 8 1 
4 6 . 6 7 
4 . 9 
1 9 . 8 6 
4-Alkylamino-l-H-tetrahydrofuranyl-6-inethylthiopyrazolo 
r3,4-d*] pyrimidines (60-67) 
Compound (59, 1 g, 0.003 mol) and an appropriate amine 
(0.003 mol) was heated at 85° for 3-8 hr. The resulting 
mixture on washing with hexane furnished a crude product 
which was chromatographed over Si02 column. Elution with 
chloroform:methanol (98:2) and crystallization from ether-
hexane, afforded (60-67). In case of 6^ the reaction 
mixture was heated at 165 . The physical and spectral data 
of the compounds (60-67) are given in the annexure-A. 
6-Methylsulphonyl-4-N-substituted-1-tetrahydrofurylpyrazolo 
Q3, 4-dJl pyrimidine (68-75) 
Compounds (60-67) (0.001 mol) in dichloromethane were 
stirred with m-chlcaroperbenzoic acid (0.4 g) for about 20 hr. 
The reaction mixt. was further stirred with satd. aq. NaHCO-
for 10 hr. The organic phase were separated, dried (Na2S0^) 
and evaporated. The product was crystallized from ether-
30 
hexane to give (68-75). The physical and spectral data of 
the compounds (68-75) are given in annexure-B. 
6-Methoxy-4-N-substituted-l-H-tetrahydrofuranylpyrazolo 
[3,4-:^ J pyrimidine (76-83) 
Compounds (68-75) were refluxed with 1^ sodivim methoxide 
in methanol for 3 to 10 hr. The resulting mixture was cooled, 
neutralized with acetic acid and the solvent removed. The 
residue was dissolved in ethylacetate, washed with H^O, 
dried (Na2S0.) and solvent removed. The product obtained 
was crystallized from ether-hexane to give the required 
products (76-83). The physical properties and spectral 
values of the above compounds are given in the annexure-C. 
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ANNEXURE-A 
Compound-60 
% y i e l d : 7 6 . 5 
m . p . : 199° 
MS: 251 (M"^) 
I R ^ K B r = 3400 (-NH2) 
PMR: (DMSO-dg) : 2 . 0 - 1 . 8 5 (m, 4H, H-2 ' & H-3 ' ) , 2 . 5 ( s , 3H, 
-S-CH^) , 3 . 5 - 3 . 2 5 (m, 2H, NH^), 3 . 9 - 3 . 7 5 (m, 2H, H-4' ) , 6 . 35 
(dd, IH, H - 1 ' , 6 .5 Hz) , 8 . 1 ( s , IH, H - 3 ) . 
^ 1 0 ^ 1 3 ^ 5 ° ^ 
(MW = 251) c 
H 
N 
Found 
47.8 
4.83 
28.06 
Calculated 
47.81 
5.18 
27.89 
Compound-61 
% yield: 42.6 
m.p.: 123° 
+ , MS: 265 (M ' ) 
PMR:(CDCl2): 1.9-1.78 (m. 4H, H-2' & H-3'), 2.5 (s, 3H, 
-S-CH^), 3.07 (d, 3H, -NHCH^, 7Hz), 4.1-3.85 (m, 2H, H-4'), 
6.5 (m, IH, H-1'), 7.2 (m, IH, -NH) , 7.8 (s, IH, H-3). 
C^ -H^ t-NcOS Found Calculated 
11 15 5 
(MW =265) C 
H 
N 
49.32 
5.69 
26.30 
49.44 
5.66 
26.42 
32 
Compound-62 
% yield: 42.7 
in.p.: Oil 
MS: 369 (M"^ ) 
PMRilCDCl^): 1.97-1.66 (in, 4H, H-2' & H-3' ) , 2.2 (s, 3H, 
CH^-Ar), 2.5 (s. 3H, -S-CH^)/ 2.78 (t, 2H,-CH^-Ar), 3.7 
(m, 2H, NH-CH^), 3.9 (m, 2H, H-4 ' ) , 5.85 (m, IH, -NH-CH -) , 
6.5 (m, IH, H-1'), 7.0 (s, 4H, ArH), 7.82 (s, IH, H-3). 
C H -N^OS Found Calculated 
(MW = 369) c 
H 
N 
61.52 
6.01 
18.92 
61.79 
6.23 
18.97 
Compound-63 
% yield : 53 
m.p.: 131 
+ , MS: 319 (M-) 
PMR (CDC1-): 1.7-1.62 (m, 6H, methylene), 1.98-1.8 (m, 4H, 
H-2' & H-3'), 2.56 (s, 3H, -S-CH^), 4.1 (m, 4H, N(CH2-) & 
H-4'), 6.48 (m, IH, H-1' ), 7.85 (s, IH, H-3). 
^15«21^°^ 
(MW = 319) c 
H 
N 
Found 
56.02 
6.58 
21.90 
Calculated 
56.11 
6.58 
21.94 
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Compound-64 
% yield: 57 
m.p.: 131° 
MS: 321 (M"^ ) 
PMR(CDCl2): 1.92-1.78 (m, 4H, H-2' & H-3') , 2.55 (s, 3H, 
-S-CH^), 3.72-4.3 (bm, lOH, 8H-morpholine & 2H, H-4'), 6.6 
(m, IH, H-1'), 7.78 (s, IB, H-3). 
C .H N 0 S Found Calculated 
(MW = 321) c 
H 
N 
52.09 
5.72 
22.63 
52.34 
5.92 
21.81 
Compound-65 
% yield: 53 
m.p.: Oil 
MS: 415 (M"*") 
PMRCCDCl^): 2.0-1.8 (m, 4H, H-2' & H-3'), 2.55 (s, 3H, 
-SCHJ), 2.85 (t, 2H, -CH2-Ar), 3.42 (m, 2H, -N-CH2-)' 
3.9 (s, 8H, 2OCH2 & H-4'), 6.55 (m, IH, H-1'), 6.7 (s, 
3H, ArH), 7.7 (s, IH, H-3), 7.9 (bs, IH, -NH) . 
S0»25V32 
(MW = 415) c 
H 
N 
Found 
57.83 
6.1 
16.82 
Calculated 
57.83 
6.02 
16.84 
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Compound-66 
% yield: 61.5 
m.p.: Oil 
MS: 334 (M"*") 
PMR:(CDC1^): 1.92-1.8 (m, 4H, H-2' & H-3' ) , 2.28 (s, 3H, 
N-CH ), 2.45 (m, 4H, methylene), 2.52 (s, 3H, S-CH^)/ 3.88 
(t, 4H, methylene), 4.02 (m, 2H, H-4'), 6.65 -{dd, IH, H-1 • ) , 
7.79 (s, IH, H-3). 
C^^H 2NgOS Found Calculated 
(MW = 334) c 
H 
N 
53 .90 
6 .59 
24 .92 
5 3 . 9 2 
• 6 .59 
2 5 . 1 5 
Compound-67 
% yield: 51 
m.p.: 92° 
MS: 396 (M"^ ) 
PMR (CDCI3): 1.9-1.76 (m, 4H, H-2' & H-3*), 2.55 (s, 3H, 
S-CHo), 3.22 (t, 4H, -NC;^^-2~ ), 3.98-3.72 (m, 6H, 
CH -
-NC^ ^ & H-4'), 6.55 (m, IH, H-1'), 6.68 (m, 3K, Ar-H) , 
CH2 
7.23 (m, 2H, Ar-H), 7.8 (s, IH, H-3). 
C-^H„.N^OS Found Calculated 
20 24 6 
(MW = 396) c 
H 
N 
6 0 . 5 1 
6.00 
21 .9 
6 0 . 6 6 
6.07 
2 1 . 2 1 
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AmEKURE-B 
Compound-SB 
% y i e l d : 50 
m . p . : 182° 
MS: 283 (M"^) 
IR: 3400 (-NH2), 1395 (SO^CH^) 
PMR:(CDCl2 +DMSO-dg) : 1 . 8 6 - 1 . 6 9 (m, 4H, H-2 ' & H - 3 ' ) , 
2 .85 ( s , 3H, SO2-CH3), 3 .82 (m, 2H, H-4' ) , 6 . 5 5 (m, IH, 
H - 1 ' ) , 8 . 2 - 7 . 9 (m, 3H, H-3 & -NH ) . 
^10^13^5°3^ Found C a l c u l a t e d 
(MW = 283) c 
H 
N 
4 2 . 8 1 
4 . 4 9 
2 4 . 6 5 
4 2 . 8 6 
4 . 5 9 
2 4 . 7 3 
Compound-69 
% y i e l d : 30 
m . p . : 161 
MS: 297 (M"*") 
PMR: (CDCl^): 2 . 0 - 1 . 8 2 (m, 4H, H-2 ' & H - 3 ' ) , 2 . 9 ( s , 3H, 
-SO^CH^), 3 .05 (d, 3H, -NH-CH^)/ 3 .85 (m, 2H, H^ , ) , 5 . 2 -
, 4 . 9 (m, IH, -NH), 6 .55 (m, IH, H - 1 ' ) , 8 .05 ( s , IH, H - 3 ) . 
^ 1 ^ 1 5 ^ 3 2 
(MW = 297) c 
H 
N 
Found 
4 4 . 1 
• 5 .02 
2 3 . 4 9 
Ci a l c u l a t e d 
4 4 . 4 
5.05 
23 .57 
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Compound-70 
% yield: 55 
m.p.: 240-51° (d) 
MS: 409 {M"*'") 
mR: (CDCI3 +DMSO-d^): 1.89-1.78 (lit, 2H, H-2 ' & H-3'), 
2.2 (s, 3H, CK^-Ar), 2.85 (s, 3H, -SO^-CH.), 2.78 (t, 2H, 
-CH^-Ar), 3.7 (m, 2H, NH-CH^-) , 4.05 (m, 2H, H-4'), 6.5 
(m, IH, H-1'), 7.05 (s, 4H, Ar-H), 7.25 (m, IH, NH), 7.8 
(s, IH, H-3). 
C^gH^^N^O^S Found Calculated 
(MW = 409) c 
H 
N 
5 5 . 7 5 
5 .62 
1 7 . 1 1 
55 .68 
5 .66 
1 7 . 0 3 
Compound-71 
% y i e l d : y i 
m . p . : >300° 
.+ , MS: 351 (M') 
PlviR: (CDCl^+DMSO-dg) : 1 . 7 - 1 . 6 2 (m, 6H, m e t h y l e n e ) , 1 . 9 - 1 . 7 3 
(m, 4H, H-2' & H - 3 ' ) , 2 .85 ( s , 3H, -SO -CH ) , 4 . 2 5 - 4 . 1 (m, 
CH 
4H, - N \ ^ ) , 6 .63 (m, IH, H - 1 ' ) , 7 . 8 ( s , IH, H - 3 ) . 
Found C a l c u l a t e d 
^15^ 
(MW 
% 
'2l' '5°3^ 
= 351) c 
H 
N 
5 1 . 4 3 
6 . 1 
1 9 . 7 8 
51 .25 
6 .00 
1 9 . 9 5 
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Compound-72 
% yield: 54.5 
m.p.: >300° 
MS: 321 (M"^ ) 
PMR(DMSO-d^) : 1.B2-1.7 (m, 4H, H-2 ' & H-3 ' ) , 2.83 (s, 3H, 
-SO -CH^), 3.92-3.70 (m, lOH, 8H methylene & 2H, H-4'), 6.55 
(m, IH, H-1'), 7.8 (s, IH, H-3). 
C, .H.oNcO.S Found Calculated 
14 19 5 4 
(MW = 353) c 
H 
N 
47.35 
5.42 
19.80 
47.59 
5.38 
19.83 
Compound-
% yield: 
m.p. : 
MS: 
-73 
67 
124° 
447 (M"^) 
PMRCCDCI^): 1.9-1.78 (m, 4H, H-2' k H-3'), 2.85 (s, 3H, 
-SO2-CH2)/ 2.75 (t, 2H, -CH2-Ar), i.42 (m, 2H, HN-CH2-) . 
3.78 (s, 6H, ^-O-CH^), 4.1 (m, 2H, H-4'), 6.65 (m, IH, 
H-1'), 6.9-6.76 (m, 3H, Ar-H) , 7.95 (s, IH, H-3). 
^20»25^5°5S 
(MW = 447) c 
H 
N 
Found 
53.62 
5.51 
15.69 
Calculated 
53.69 
5.59 
15.66 
38 
Compound-74 
% y i e l d : 3 6 . 5 
m . p . : >300 
MS: 366 (M"*") 
PMR:(CDC1^) : 1 . 9 3 - 1 . 7 9 (m, 4H, H - 2 ' & H-3 ' ) , 2 . 4 ( s , 3H, 
CH 
N-CH ) , 2 . 8 5 ( s , 3H, -SO„-CH ) , 3 . 2 5 (m, 4H, N ^ ' ^ ) , 
. C H / ^ ^ C H 
4 . U 5 (m, 6H, 4H, -N^^ ) & 2H, H-4 ' ) , 6 . 5 5 (m, IHT H-1 ' ) , 
CH. 
7 . 7 8 ( s , I H , H - 3 ) . ^ 
^15"22V3S 
(MW = 366) C 
H 
N 
Found 
49.18 
6.07 
22.90 
Calculated 
49.18 
6.01 
22.95 
C o m p o u n d - 7 5 
% y i e l d : 28 
m . p . : O i l 
MS: 428 (M"^) 
PMR{CDC1 ) : 1 . 9 - 1 . 7 9 (m, 4H, H - 2 ' & H - 3 ' ) , 2 . 8 8 ( s , 3H, 
CH 
- S O 2 - C H 2 ) , 3 . 6 - 3 . 3 (m, 4H, -N <[ ) , 4 . 1 (m, 6H, 4H, 
c H CH~ 
N-(^ - ^ & 2H, H - 4 ' ) , 6 . 6 (m, IH, H - 1 ' ) , 6 . 8 5 (m, 3H, A r - H ) , 
7 . 1 5 (m, 2H, A r - H ) , 7 . 9 ( s , IH , H - 3 ) . 
S0«24V32 
(MW = 428) C 
H 
N 
Found 
56.12 
5.60 
19.60 
Calculated 
56.07 
5.61 
19.63 
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ANNEXURE-C 
CcT^qur. d--76 
^^  y i e l d : 2'". 
, -, - ,,o > - , 
l-.'H (C: J l^ - r . 'VSO-^ i^) : l . S c , _ i , 7 2 (p , 4H, H - 2 ' & H-3 ' ) , 3 . 6 
( t , 2H, H - 4 ' } , 3 . 8 ( s , 3 B , - 0 - C H . J , 6 . 4 8 (xn, IH , H-1 ' ) , 
- ^ . 2 - 6 . 9 3 ( b s , 2H, NE2) , 7 . 9 5 ( s , IH, H--3) . 
.0^13^S°2 
(KVv^ c 
H 
N 
Fo-cnd 
51.00 
5.48 
29.78 
Calculated 
51.06 
5.53 
29.78 
Compo'und-77 
% 3 ' i e l d : 42 
m . p . : 1 3 / 
MS; 249 (MI") 
PHRMCDCl^) : 2 . 1 - 1 . 8 1 (m, 4H, H - 2 ' & H-3 ' ) , 3 . 0 5 (d, 3H, 
HNCH^, 4 . 5 H 2 } , 3 . 8 ( s , 3 ^ , OCH^), 4 . 1 5 - 4 . 0 (m, 2H, H - 4 ' ) , 
6 . 4 5 (dd, IH , E - 1 ' , 6 . 5 J i z ) , 7 . 7 ( s , IH , H - 3 ) . 
(MW = 249) C 
H 
N 
Found 
53.0 
6.12 
28.06 
Calculated 
53.01 
6.02 
28.11 
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Compound-78 
% yield: 52 
m.p.: 140 
MS: 353 (M"*") 
PKR: (CDCl^+DMSO-dg): 1.82-1.71 (m, 4H, H-2' & H-3'), 2.25 
(s, 3H, CH--Ar), 2.65-2.50 (m, 2H, -CH2-Ar), 3.2 (m, 2H, 
HN-CH^-), 3.72-3.51(m, 3H, -NH- & H-4'), 3.9 (s, 3H, -O-CH^), 
6.55 (dd, IH, H-1', 5.6 Hz), 7.05 (s, 4H, Ar-H), 7.9 (s, 
IH, H-3). 
^19"23N5°2 
(MW = 353) c 
H 
N 
Found 
64.51 
6.34 
19.90 
Calculated 
64.59 
•6.51 
19.83 
Compound-79 
% yield; 31 
m.p.: Oil 
MS: 304 (M' + 1) .+ 
PMR:(CDC1 ): 1.63-1.48 (m, 6H, methylene), 1.94-1.70 (m,4H, 
H-2' & H-3'), 4.1-3.9 (m, 9H, -0-CH-, H-4' it -Nf ), 
CH 
6.5 (m, IH, H-1'), 7.85 (s, IH, H-3). 
^15«2lN5°2 
(MW = 303) c 
H 
N 
Found 
59.40 
6.88 
21.10 
Calculated 
59.41 
6.93 
23.10 
41 
51.8 
6.01 
22.92 
51.8 
6.23 
22.95 
Cornpound-80 
% yield: 29 
:r,.p. : 141 
MS: 305 (M"*^ ) 
?MR:(CDCl2): 1.9-1.78 (m, 4H, H-2' & H-3') , 4.2-3.72 (m, 
13H, 0-(^ H / 8 H methylene & H-4 ' ) , 6.6 (dd, IH, H-1', 6.0 Hz), 
7.78 (s, IH, H-3). 
C .H gN 0^ Found Calculated 
(MW = 305) C 
H 
N 
Compound-81 
% yield: 46 
m.p.: 141 
MS: 399 (M"^ ) 
PMR (CDCl^): 1.86-1.7 (m, 4H, H-2' & H-3'), 2.85 (t, 2H, 
-CH^-Ar), 3.0-2.9 (m, 2H, -N-CH2-), 3.78 {s, 6H, 2O-CH2), 
3.9 (s, 3H, O-CH^), 6.65 (dd, IH, H-1', 6.0 Hz), 6.7 (s, 3H, 
Ar-H), 7.67 (s, IH, H-3). 
^20"25^°4 
(MW = 399) C 
H 
N 
Found 
60.1 
6.29 
17.30 
Calculated 
60.15 
6.27 
17.54 
42 
Compound-82 
% yield: 42.7 
iTi.p.: O i l 
V£: 31P (M~) 
PMR:(CDC2^): 1.82-1.7 (m, 4H, H-2' & H-3' ), 2.0 (s, 3H, 
-K-CH, ), 2.89 (t, 4H, K< ^ ), 3.95 (s, 3B, 0-CH ), 4.1-
/^~2 
3.7 (ITS, 6H,H-4' & -N<^ ), 6.5 (dd, IH, H-1' , 6Hz), 7.9 
[s, IH, H-3). 
CH^ 
CT^H„„N,0_ Found Calculated 
ID 22 6 2 
(MW =318) c 
H 
N 
56 .50 
6 .86 
26 .39 
5 6 . 6 0 
6 .92 
26 .42 
.+, 
Compound-83 
% yield: 33.7 
m.p.: Oil 
MS: 380 (M"^ ) 
PKuR: (CDCl + DMSO-d.) : 1.8-1.69 (m, 4H, H-2' & H-3'), 
CH 
3.15 (t, 4H, -N<^ ~^ ), 3.9 (s, 3H, -0-CH ) , 4.05-3.8 
CH 
(m, 6H, NC^ & H-4'), 6.5 (m, IH, H-1'), 6.8 (d, 3H, 
Ar-H), 7.2 (d, 2H, Ar-H) , 7.82 (s, IH, H-3). 
C„„H„.N,0„ Found Calculated 
20 24 6 2 -
{MW = 380) C 
H 
N 
6 3 . 2 
6 .39 
22 .30 
6 3 . 1 6 
6 .32 
2 2 . 1 0 
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.1 i' I I ] . . . I 
% yield: 61.7 
:ri.p,: 168-70° (d) 
y,S: 263 (F' ) 
Pi.'.--:: (CDCl.): 0.95 (r, 3H, CH_-CH^, 7Hz) , 1.8-1.74 (m, 4H, 
H-2' <^  H-3'), 3.89-3.82 {m, 2E, H-4 ' ) , 4.27 {q, 2H, CH2-CH2-, 
5Hz), 5.75 (bs, 2H, NH^) , 6.49 (m, IH, H-1' ) , 7.7 (s, IH, 
H-3) . 
C,„K,^N_0„ Found Calculated 
12 1/52 
(KW = 263) c 
H 
N 
54 .78 
6 .12 
2 6 . 5 
5 4 . 7 5 
< 6 .46 
2 6 . 6 1 
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Biological Activity 
4-Alkyl&niino-6-raethyltaio-l~tetrahydrofuranyl pyrazolo 
r?,4-d~| pyririidine (60-67), 4-alkylamino-6-methylsulphonyl-
l-tetrehyorcf aranylpyrazolo [ 3, 4-^ d] pyrimidine (68-75) 
ar.c; 4-r.lkylamino-6-methoxy-l-tetrahydrofuranylpyrazolo 
r?,4-dJ pyrimidine (76-83) reported in this chapter were 
examined for their antiviral properties by Dr. N.M. Joshi 
in the Virology Division and passive cutaneous anaphylaxis 
(?CA) test were performed by Dr. K. Kar in the Pharmacology 
Division of Central Drug Research Institute, Lucknow. 
Antiviral activity 
The antiviral activity of the compound synthesized was 
determined against Ranikhet disease virus (RDU) iri vitro 
according to Babbar ' procedure. The results are 
summarised in the Table-2. 
Antiviral activity of 4-N-substituted-6-methylthio-l-tetra-
hydrofuranylpyrazolo [_3,4-d1 pyrimidine (60-67) 
S.No. X_(4-N-substituent) Antiviral activity 
60 Amine Inactive 
61 Methylamine Inactive 
62 p-Tolylethylamine 25% 
63 Piperadinyl ~ Inactive 
contd.. 
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(contd...Table 2) 
64 Morpholinyl 30% 
65 3,4-Dimethoxyphenyl 
p-«thylamine Inactive 
4 
66 N -methylpiperazinyl Inactive 
4 
67 N -phenylpiperazinyl Inactive 
Table 3: 6-Methylsulphono-4^6ubstituted-l-tetr&hyarofuranyl 
pyrazolo fs, 4-dl pyrimidine (6_8-7jJ 
S.No. X Antiviral activity 
60 
100 
26 
100 
Inactive 
68 
69 
70 
71 
72 
73 
74 
75 
Amine 
Methylamine 
p-Tolyethylamine 
Piperadinyl 
Morpholinyl 
3,4-D imethoxyphenyl-
ethylaiTiine 
4 
N -Methylpiperazinyl 
4 
N -Phenylpiperazinyl 20 
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Table 4: 6-Metlioxy-4-N-substituted-l-tetrahydrofuranyl 
pyrazolo r3,4-d"] pyrimidine (76-83) 
S.No. X Antiviral activity 
76 Amine 33 
77 Methylamine 
78 p-Tolyethylamine 
79 Piperadinyl 100 
80 Morpholinyl 0 
81 3,4-Dimethoxyphenylethylamine 
4 
82 N -Methylpiperazinyl 
4 
83 N -Phenylpiperazinyl 
Passive cutaneous anaphylaxis test 
The test was performed in groups of 4 male mice (18-22 g) 
per dose of the test compound. Hyperimmune antiserum contain-
ing heat stable heterocytotropic antibody against egg albumin 
was raised in rabbits. 0.1 ml of anti-serum at a dilution of 
1 in 10 normal saline was injected intradermally into the 
back of freshly shaved dorsal surface of each mouse. The 
test compounds were suspended in 0.2 ml of gum acacia and 
administered orally 1 hr before antigenic challenge (egg 
albumin). The severity of PCA reactions was assayed by 
measuring the mean diameter of blue coloration 30 min after 
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the intervenous challenge of antigen (50 mg/kg) solution 
containing 0.5% Evan's blue. Results was expressed as 
percentage inhibition of the PCA obtained in control groups 
of animals receiving only saline. Mepyramine nialeate, an 
antihistamine agent and disodium chromoglycate, an anti-
allergic drug, were used as reference standards. The 
results of the activity are recorded in Table-5. 
Table-5: PCA inhibition of 6-methylthio-4-N-substituted 
1-tetrahydrofuranylpyrazolo C3,4-d_"l pyrijnidine 
(60-67) 
S.No. X % PCA inhibition 
(dose mg/kg) 
60 Amine 79 (200) 
61 Methylemine 33 
62 p-Tolyethylamine 54 
63 Piperadinyl 25 
64 Morpholinyl 39 
65 3,4-Dimethoxyphenylethylamine 54 
4 
66 N -Methylpiperazinyl 
4 
67 N -Phenylpiperazinyl 
Mepyramine maleate 7 9 (25) 
disodium chromoglycate 25 (50) 
CHAPTER-3 
3 . 0 SYNTHESIS OF 4-ALKYLAMINO-6-METHYLTHIO/METHOXY-
l-(^-D-RIBOFURANOSYL) PYRAZOLO f 3 , 4-^yPYRIMIDINE 
AND THEfR BIOLOGICAL ACTIVITIES 
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3.1 Introduction 
Nucleosides are components of many biological molecules 
that are present in the cells of living organisms. They are 
involved in protein synthesis, storage and transfer of 
genetic information. It is expected that the analogues of 
naturally occurring nucleosides and/or of nucleosides 
exhibiting biological activities may lead to new therapeutic 
agents. 
Among the various structural variants currently being 
studied, pyrazolo r3,4-dj pyrimidine have received renewed 
55 
attention due to their wide spectrum of activity . . 
Allopurinol (pyrazolo[_3,4-_dJ pyrimidine-4-one) (^ ) an 
analogues of hypoxanthine is an inhibitor of purine catabolic 
62 
enzyme, xanthine oxidase . and is used for the treatment 
of hyperurecemia responsible for gout . 4-Amino 
pyrazolo 13,4-^ 'I pyrimidine ribosides (90) an analogue of 
adenosine, is active against several species of leishmania 
65-70 
89 
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3.2 Present work 
In view of the significant biological activities of 
pyrazolo r3,4-d~] pyrimidine derivative, it was thought 
worthwhile to prepare 4-^alkylamino-G-methylthiopyrazolo 
r3,4-dl pyrimidine ribosides (91) and 4-amino-5-methoxy-
pyrazolo C3,4-dJ pyrimidine riboside (22.). The compounds 
(91) and (92) are also related to spongosine (23.), an 
unusual nucleoside isolated from marine sponge Cryptolethia 
8 
crypta which exhibits anticancer and vasodepressor activities, 
MU{^ 
C^X" 
KT. 
H H : 
»A>M^>--U^ 
91 
OH \^(\r-OH 
H(? 'O^ y^O OH 
92 
NV4 
S3 
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3.3 Synthesis of 4, 6-diinethylthio-l-(3-D-ribofuranosyl) 
pyrazolo^,4-dlpyrimidine 
Literature survey revealed that pyrazolo r3,4-^| 
pyrimidine nucleosides have been synthesised by following 
three procedures. 
(i) Thermal fusion, 
(ii) Lewis acid catalysed condensation 
(iii) Chloromercuric complex procedure 
We have synthesised the title compound following the 
latter two procedures. 
3.3.1 Chloromercuric complex procedure 
Chloromercuric complex (94)was obtained by reaction of 
HgCl2 •^'•'*'^  4, 5-dimethylthiopyrazolo [| 3, 4-_d'] pyrimidine in 
presence of NaOH in good yield. l-O-Acetyl-2,3,5-trio-O-
benzoyl-D-ribose (1Op) required for condensation was pre-
71 pared according to procedure of Kissman et^  al_. Compound 
100 on treatment with HCl gas in dichloromethane afforded 
l-chloro-2,3,5-tri-O-benzoyl-D-ribose (95). 
Condensation of 94_ with l-chloro-2, 3, 5-tri-O-benzoyl-
D-ribofuranose (95) in boiling toluene gave a mixture of 96^  
(yield, 60%) and 101 (yield, 5%) . The compound 96^  and 101 
were assigned as 3- and a-anomers respectively, based on 
their spectral data, which have been discussed latew,; , 
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SCH3 SCHj 
V^ O v l - * ' ^ 
57 
SCVA3 SCH^ 
.C^3^ 
M'--
sA fW^^^-S^ / 
•V \c>V 
PX) op . 
96 97 
V4HR. 
CV^'^ 
P °^" 
Ho OH 
9 1 : R'=H 
98_: R'=CH3 
2 2 : R'=NH 'iiLsCOCgHg 
o\A 
Scheme-3 
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Treatment of the protected nucleoside (96) with meth-
anolic ammonia at ambient temperature gave 4,6-dimethylthio-1-
(B-D-ribofuranosyl)pyrazolo [^3/4-2d~] pyrimidine (97^ ) in 70% 
yield. 
72 3.3.2 BFiOEt_ Catalysed condensation 
Condensation of 4, 6-dimethylthiopyrazolo [^3, 4-d]]pyri-
midine (57) with 100_,catalysed with freshly distilled BF-OEt , 
a Lewis acid gave a mixture of 9;^  (yield, 60%) and 101 
(yield, 10%). In order to improve the yield of desired 
product 96_, reaction was carried out in CH-CN, and dichloro-
methane. However, there was no improvement in the yield. 
3.4 Synthesis of 4-alkylamino-6-methylthio/methoxy-l-
(B-D-ribofuranosyl)pyrazolo [^3,4-^ pyrimidine (91, 98, 99) 
The compounds (91_, 98_ and 22.) were prepared as given in 
Scheme-3 and 5. 
Treatment of 91_ with NH at 120° in a steel bomb afforded 
4-amino-6-methylthio-l- (^-D-ribofuranosyDpyrazolo fs, 4-dn 
pyrimidine (9|1.) in 90% yield. 
Direct amination of _96 also gave compound (91) . However, 
better yield was obtained when the reaction was carried out 
73-74 
m two steps. Amination of 97_ with methylamine and 
hydrazine hydrate furnished the compounds (98) and (99) in 
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^CH3 
C V A | A w > - ^ BF30Et2 
CH3NO2 
9.0 
oR, 
^ ^ 2 
SCH3 
CV^-'^wJ^^ 
+96 
101 
OR' 
SCH^ 
OH 
103 102 
R' = COPh 
R" = COMe 
Scheme-4 
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tAH^ 
OH 
VAH 
NHCOCH^ 
•^  J L 
104 
%kuX^ 
0^^% 
OCOC V\' 
^ ^ 3 0 c 6 OCOC^, 
106 NH- 105 
O^^ 
H o OH 
93 
Scheme-5 
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68 and 19% yield respectively. The compound (9_9^) was, however, 
obtained in 70% yield, when the compound (26^ ) was treated 
with hydrazine hydrate. 
75 Acetylation of compound (^ ) with acetic anhydride 
and pyridine gave the tetraacetyl derivative (104) in 80% 
yield. KMnO^ oxidation of 104 in acetic acid afforded the 
methylsulphone (105). Compound (105) on refluxing with 
sodium methoxide in methanol gave the desired product (93). 
3.5 Position and configuration of sugar moiety in 4,6-
dimethylthio-pyrazolor3, 4-d"l pyrimidine ribosides 
In the synthesis of compound (92) the possibilities for 
the attachment of sugar at N-1 or N-2 have been decided using 
the UV-spectroscopic technique. 
Robins and Cheng have prepared N-1 and N-2 substituted 
pyrazolo L 3, 4-_dJ pyrimidine by /unambiguous method and corr-
elated their UV absorption pattern with nucleoside to decide 
Ho OH 
97 
their point of attachment. This correlation has been shovm 
in Table 6. 
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Tab le 6 ; UV a b s o r p t i o n of s u b s t i t u t e d p y r a z o l o [ "3 ,4-^ j 
S.No. 
107 
p y r i m i d i n e r i b o s i d e s 
Compound 
LJLJ/ 
vmax 
i n nm 
268 
Ref . 
56 
88 
-L 
N(tH3); 
CH3 294 56 
108 
MHi to 261 
277 
56 
109 
110 
111 
oH 
H H , Ho bH 
O 
261 
264 
275 
284 
76 
76 
76 
57 
59 Schmidt and coworker have further shown that 2-alkyl 
pyrazolo fS,4-dlpyrimidine exhibit a bathochronic shift of 
15-25 nm compared to 1-alkyl derivative. The comparison of 
UV absorption of 4,6-dimethylthio-l-{&-D-ribofuranosyl) 
pyrazolo r3,4--cn pyrimidine {SlJ with compounds (109, 110 
and 111) have suggested that the glycosylation has occurred 
at N-1. 
Further, the a and &-configuration of the anomers was 
decided on the basis of the coupling constant (J-value)of 
anomeric proton. The coupling constant is dependent on 
dihedral angle (0) between the bond under investigation. It 
has been observed that dihedral angle for a-anomer vary 
between 0 /3 U^^ and for 3-anomer it varies between 75 
IP ^120 . Therefore, from Karplus equation the .^-nucleoside 
77 
should have lower J-value as compared to nfc- nucleoside 
Further the signal for anomeric proton in case of g-anomer 
comes relatively higher field than a-isomer. 
0\r-OH 
Ho OH 
97 
StHj, 
OH 
101 
58 
97: 6 = 6.25 (Anomeric proton) 
'^l',2' = (2.5 Hz) 
101 5 = 5.90 (Anomeric proton) 
'^l',2' " ^^-^ ^^^ 
Thus from the above data we have concluded that com-
pound (101) is a-isomer and compound (97) is g-isomer. 
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3.6 Experimental Procedure 
Melting points were taken with Biichi capillary apparatus 
(silicone bath) and were uncorrected. UV spectra were re-
corded on a Perkin Elmer-202 spectrophotometer (Xmax in nm); 
IR spectra on a Perkin Elmer 157 grating infracord (\)max cm" ) . 
The PMR spectra were recorded on a Perkin Elmer-360L at 60 MHz 
(Chemical shift 6 scale). The compounds were routinely checked 
on silica gel'plates and spots were located either under UV 
lamp, or by iodine vapours or by spraying with 10% sulphuric 
acid in ethanol followed by heating at 100 or by spraying 
with a mixture of ^ -anisaldehyde {2%) and sulphuric acid 
(10%) in ethanol followed by heating at 100°. Evaporation 
of solutions were carried out under reduced pressure with 
the bath temperature below 35 . 
Ribosylation of 4, 6-dimethylthiopyrazolo f 3,4-_d]pyrimidine 
(Scheme-3) 
Preparation of chloromercuric complex of 4,6-dimethylthio-
pyrazolo p , 4 -dl pyrimidine (94) 
4, 6-dimethylthio pyrazolo[3, 4-^ pyrimidine (57) (2.0g, 
0.007 mol) was added as a suspension in 50% aqueous ethanol 
(40 ml) to a solution of mercuric chloride (2.2 g) in the 
same solvent (32 ml). To the stirred suspension was added 
60 
IN NaOH till pale yellow colour appears. After 1.5 hr mix-
ture was filtered and washed with water, ethanol and finally 
with ether, dried in vacuo (3.27 g, 835$). 
C^Brjti^S 2^301 Found Calculated 
(MW = 417.5) C 20.5 20.12 
H 1.98 1.69 
Synthesis of 4,6-dimethylthio pyrazolo ^3,4-d^ pyrimidine 
ribosides 
To an azeotropically dried suspension of chloromercuric 
complex (94) (5 g, 11.3 mmol) of 4,5-dimethylthiopyrazolo 
r3,4-J]] pyrimidine (57) in anhydrous toluene (100 ml) was 
added slowly l-chloro-2,3,5-tri-O-benzoyl-D-ribofuranose 
(95) (9 g, 18.7 mmol) in anhydrous toluene (50 ml) at 60 . 
The temperature was raised to 140 after addition and the 
refluxing continued for 4 hrs. The resulting mixture 
filtered while it was hot. The solvent from the filtrate 
was evaporated iri vacuo to give a gummy mass which was 
taken in CHCl (300 ml), washed with aqueous solution of 
KI (30%, 2x100 ml), water and dried (Na2S0^). Evaporation 
of solvent gave a mixture (5.8 g) of ribosides. 
4,6-Dimethylthio-l-(2',3',5'-trio-0-benzoyl -a-D-ribofuranosyl 
pyrazolo (^ 3,4-d]] pyrimidine (101) 
The mixture of ribosides (5.8 g) was chromatographed on 
61 
SiO {250g ) column. Elution with CHCl^rMeOH (99.5:0.5 v/v) 
gave the riboside (101) as colourless foam (yield 0,37 g; 
5%) . 
m.p.: 82-3 
MS: 657 (M'^+I ) 
UV(MeOH) : 263, 230 
IR (KBr): 1740 (C=0) 
PMR: (CDCI3): 8.10-7.70 (m, 6H, H-3 & Ar-H), 7.6-7.1 (m, • lOH, 
Ar-H), 6.71 (d, IH, H-1', J^ ,^ ^, = 2Hz), 6.35-6.25 (m, 3H, 
H-5' & H-4'), 2.62 (s, 3H, S-CH^) / 2.55 (s, 3H, S-CH3) . 
C ^H gN^ O-^ S Found Calculated 
(MW =656) C 
H 
N 
Further elution of the column with CHCl2:MeOH (99:1, 
v/v) gave the riboside (9_6) / colourless foam (yield 4.4 g, 
60%), m.p. 85-6°. 
MS: 657 (M''"+1 ) 
UV (MeOH) : 265, 230 
IR(KBr) : 1740 (C=0) 
PMR(CDC1 ): 8.10 (s, IH, H'3), 8.05-7.70 (m, 5H, Ar-H), 
7.52-7.15 (m, lOH, Ar-H), 6.70 (d, IH, H-1', J^ , ^, = 1.8 Hz), 
6.35-6.15 (m, 2H, H-2' & H-3'), 4.82-4.38 (m, 3H, H-4' & 
H-5'), 2.55 (s, 3H, S-CH^)/ 2.5 (s, 3H, S-CH^)-, 
6 0 . 6 
4 .2 
8 .6 
6 0 . 4 
4 . 2 
8 .5 
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(MW = 656) c 
H 
N 
Found 
60.4 
4 . 8 
8 .4 
Calcu la t ed 
60.4 
4 . 2 
8 .5 
Boron trifluoride etherate catalysed condensation method 
(Scheme-4) 
A mixture of 4,6-dimethylthio-pyrazolo C3,4-d~l pyrimidine 
(57) (1.6 g, 7.8 mmol) and l-O-acetyl-2,3,5-tri-O-benzoyl-D-
ribofuranose (100) (3.9 g, 7.8 mmol) and dry CH NO (100 ml) 
was refluxed. To it was added freshly distilled BF-OEt^ 
(2 ml, 7.7 mmol) and refluxing continued for 1 hr. The 
solvent from the resulting mixture was evaporated under 
reduced pressure. The residue was taken in ethyl acetate 
(200 ml), washed with aqueous NaHCO- (2x100 ml), water 
(2x100 ml) and dried (Na2S0.). Removal of the solvent gave 
a mixture of ribosides which was chromatographed over a column 
of (150 g) Si02 as above. Elution of the column with CHC1-: 
MeOH (99,5:0.5 v/v) gave "^-isomer (101) (yield, 10%) followed 
by )&-isomer (£6) (yield, 60%). 
Condensation of 52 with 100 in CH CN gave 101 (yield 
12%) and 9_6 (yield, 58%) and in dichloromethane gave £6 
(yield, 40%) and 1_01 (yield, 5%) . 
4,6-Dimethylthio-l-(^-D-ribofuranosyl) pyrazo lo [3,4-d]' 
pyrimidine (97) 
A mixture of (95) (4 g) and methanolic ammonia (150 ml, 
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MeOH saturated with NH at 0 ) was kept at ambient temper-
ature for 12 hr. The methanol and excess of ammonia were 
removed under reduced pressure and the product subjected to 
flash chromatography on Si02 (18 0 g) column. Elution with 
CHCl :MeOH (94:6, v/v) afforded (97_) (yield 1.25 g, 60%). 
m.p.: 185 
MS: 344 (M"^ ) 
UV (MeOH) : 278 
IR(KBr): 3380 (OH) 
PMR(CDCl2): 8.55 (s, IH, H-3) , 6.25 (d, IH, H-1 ' , J^ , ^,^-
2.5 Hz), 4.5-4.15 (m, 2K, H-2' & H-3'), 4.3-3.88 (m, 2H, 
H-4' & OH), 3.79 (m, 2H, H-5' ), 2.60 (s, 3H, SCH ) , 2.50 
(s, 3H, -S-CH^) . 
^12«16N4°4S2 
(MW = 344) c 
H 
N 
Found 
42.4 
4 .7 
15.9 
Calculated 
41.9 
4 . 7 
16.3 
4-Amino-6-methylthio-l-(B-D-ribofuranosyl)pyrazolo [3,4-d| 
pyrimidine (91) 
A mixture of 22. (1-5 g, 4.5 mmol) and methanolic ammonia 
(30 ml, MeOH saturated with ammonia at 0 ) was heated at 120 
in a steel bomb for 16 hrs. The methanol and excess of 
ammonia were removed under reduced pressure. The product 
was crystallized from EtOH to give the riboside (.91) (yield, 
0.8 g, 90%) . 
64 
m.p.: 240 
MS: 313 {M"*") 
UV(MeOH): 276, 242 
IR(KBr): 3200-3500 (OH, NH ) 
PMR(DMSO-d^): 8.05 (s, IH, H-3) , 7.4 (bs, 2H, NH^) , 6.15 
(d, IH, H-1', J^ , 2, = 5Hz), 5.00-4.21 (m, H-2', H-3' & 
OH), 4.15-3.82 (m, IH, H-4 >), 3.25 (m, 2H, H-5'), 2.49 
(s, 3H, S-CH^) . 
^11^15^5^4^ Found Calculated 
(MW = 313) c 
H 
N 
4 2 . 5 
4 . 5 . 
2 2 . 8 
4 2 . 2 
4 . 8 
22 .4 
The compound (91) (yield 0.4 g, 60%) was also prepared 
directly from (96) (1.5 g, 4.5 mmol) by heating with methan-
olic-ammonia (40 ml) at 120° for 18 hr. 
4-Methylamino-6-methylthio-l- 0-D-ribofuranosyl) pyrazolo 
[3,4-d3 pyrimidine (_££) 
A mixture of 97_ (0.8 g, 2.3 mmol) and methylamine 
(8 ml, 40% aqueous) was heated at 85° in a steel bomb for 
2 hr. The excess of reagent was removed under reduced 
pressure and the crude product was chromatographed on SiO.^  
(120 g) column. Elution with CHCl^zMeOH (9:1, v/v) gave 
98 (yield, 0.6 g, 68%) as colourless needles (EtOH). 
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m . p . : 132 
MS: 327 (M"*") 
IR(KBr) : 3400 (OH, NH) 
PMR(CDC1 +DMSO-d^): 8 .35 ( s , IH, K-3) , 7 .8 (bs , IH, NH) , 
5 ,72 (d, IH, H - 1 ' , J ^ , 2 .= 3Hz), 4 . 5 5 - 4 . 3 9 (m, 2H, H-2 ' , 
& H - 3 ' ) , 3 . 8 - 3 . 5 1 (m, 3H, H-5 ' & H-4' ) , 2 . 9 (d, 3H, NH-CH^, 
J=4 Hz), 2 . 61 { s , ' 3 H , S-CH^). 
C.„H--,N^O.S Found C a l c u l a t e d 
12 17 5 4 
(MW = 327) c 
H 
N 
4 4 . 3 
5 .12 
21 .4 
44 .04 
5 .28 
2 1 . 4 1 
4-Hydrazino-6-methylthio-l- (/3-D-ribofuranosyl pyrazolo 
r3,4-_d'] pyrimidine (99) 
A mixture of 91_ (0.9 g, 2.6 itunol) and hydrazine hydrate 
(150 ml) was refluxed for 3 hr. The excess of reagent was 
removed under reduced pressure and the product chromato-
graphed over Si02 (80 g) column. Elution with CHCl-sMeOH 
(94:6, v/v) gave 99^  (yield, 0.17 g, 19%) as colourless 
granule (EtOH). 
m.p.: 143° 
MS: 329 (M"'"+1) 
IR(KBr): 3400-3300 (NH2OH) 
PMR (CDCl + DMSO-d,) : 8.50 .(s, IH, H-3), 5.80 (d, IH, 
H-1', J^, 2,= 4Hz), 4.7-4.0 (m, 2H, H-2' & H-3'), 3.62-3.49 
(m, 3H, H-4' & H-5'), 2.6 (s, 3H, S-CH^) . 
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C -Hj^ gNgO^ S Found Calculated 
(MW = 328) c 
H 
N 
3 9 . 9 
5.0 
2 5 . 8 
4 0 . 2 
4 . 9 
2 5 . 6 
The compound (99) (yield 0.42 g, 70%) was obtained 
directly from £6 (1.2 g, 1.88 mmol) by heating at 120° for 
12 hr with hydrazine hydrate (4 0 ml). 
4, 6-Dimethylthio-l- (a-D-ribofuranosyl)pyrazolo[^3, 4-d7 
pyrimidine (102) 
A mixture of 101 (4 g, Grnmol) and methanolic ammonia 
(150 ml, MeOH, saturated with NH at 0*^) was kept at ambient 
temperature for 14 hrs. The methanol and excess of NH were 
removed under reduced pressure and the product crystallised 
from ethanol to give 102 (yield 1.47 g, 70%). 
ra.p.: 145 
MS: 345 (M'*"+1) 
UV (MeOH) : 278, 258 
IR(KBr): 34 00 (OH) 
PMR (CDCl^+DMSO-dg) : 7.85 (s, IH, H-3), 5.9 (d, IH, H^  , ^,= 
4.0 Hz), 4.7-4.58 (m, IH, H-2 ' ) , 4.48-4.35 (m, Ih, H-3'), 
4.15-3.90 (m, 2H, H-4' & OH), 3.65 (m, 2H, H-5' ), 2.6 (s, 
3H, S-CH^)/ 2.52 (s, 3H, S-CH ) . 
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C,„H, ,N.O,S^ Found Calculated 
12 16 4 4 2 
(MW = 344) c 
H 
N 
41.6 
4 . 8 
15.9 
41.9 
4 . 7 
16.3 
4-Amino-6-methylthio-l- (a-D-ribofuranosyl) pyrazolo [3, 4-d~l 
pyrimidine (103) 
A mixture of 102 (1.5 g, 4.5 nunol) and methanolic ammonia 
(150 ml) vas heated in a steel bomb at 120° for 16 hr. The 
methanol and excess of ammonia were removed under reduced 
pressure and the product crystallized from Aqueous ethanol to 
give 103 (yield 0.8 g, 90%). 
m.p.: 218° 
MS: 313 (M"*") 
IR(KBr): 3200-3500 (OH, NH2) 
PMR(DMSO-d,) : 8.09 (s, IH, H-3), 7.75 (bs, 2H, NH„), 6.05 
o —z 
(d, IH, H-1', J^  , = 6Hz), 4.73-4.41 (m, IH, H-2' ) , 4.29-
4.05 (m, IH, H-3'), 3.90-3.70 (m, IH, H-4'), 3.58-3.15 
(in, 3H, H-5' & OH), 2.45 (s, 3H, S-CH ) . 
C H^cNcO^S Found Calculated 
(MW = 313) c 
H 
N 
4 2 . 3 
5.0 
2 2 . 0 
4 2 . 2 
4 . 8 
2 2 . 4 
4-Acetamido-6-methylthio-l- (/3-D-2 ', 3 ', 5 ' -trio-O^acetyl 
ribofuranosyl)pyrazolo ["3, 4-dj pyrimidine (104) 
A mixture of 93^  (1 g, 3.2 mmol), anhyd. pyridine (15 ml) 
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and acetic anhydride (2.5 ml) was stirred at ambient temper-
ature for 20 hrs. Water (3 ml) was added to the reaction 
mixture, and excess of reagent and water removed at reduced 
pressure. The residue chromatographed on a SiO„ (80 g) 
column. Elution with chloroform methanol (98:2 v/v) gave the 
product which was crystallized from EtOH to give 104 (yield 
0.8 g, 80%). 
m.p.: 85-7° 
MS: 481 (M"!") 
IR(KBr): 1750 (0=0) 
PMR(CDCl-): 12.04 (bs, IH, NH) , 8.78 (s, IH, H-3) , 6.31 (d„ 
IH, BUI', J = 2.5 Hz), 5.75-5.55 (m, 2H, H-2' & H-3'), 
4.45-4.00 (m, 3H, H-4' & H-5'), 2.49 (s, 3H, S-CH^), 2.18 
(s, 3H, CH^-CO) , 2.02 (s, 3H, CH^-CO) , 2.00 (s, 3H, COCE^) , 
1.97 (s, 3H, COCH^). 
C,-H N^OgS Found Calculated 
(MW = 481) c 
H 
N 
4 7 . 5 
4 . 9 -
1 5 . 3 
4 7 . 4 
4 . 8 
1 5 . 6 
4-Acetamido-6-methylsulphonyl-l-(3-D-2',3',5'-tri-0-acetyl-
ribofuranosyDpyrazolo £ 3, 4-;^"7 pyrimidine (105) 
A mixture of 104 (0.2 g, 0.4 mmol), acetic acid (50%, 
10 ml) and KMnO (0.2 g), at 0°, stirred for 1 hr, ^20^ 
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(32%, 25 ml) was added to it till the colour disappeared 
and then extracted with chloroform. The chloroform extract 
was washed with water, dried (Na-SO.), and the solvent 
removed. The product, thus obtained, was crystallized from 
ethanol to give 105 (yield, 0.18 g, 75%), as colourless 
needles. 
m.p.: 114-116 
IR(KBr):'1140,, 1320 (CH2SO2) 
PMR(CDCl3+DMS0-d,) : 9.2 (s, IH, H-3), 7.1 (s, IH, NH) , 6.4 
(d, IH, H-1', J = 1.8 Hz), 5.78-5.60 (m, 2H, H-2' & 
H-3'), 4.50-4.15 (m, 3H, H-4' & H-5'), 3.29 (s, 3H, SO^CH^), 
2.25 (s, 3H, CH^CO), 2.05 (s, 3H, COCH^) , 2.02 (s, 3H, OCCH^) / 
1.9 (s, 3H, OCCH ) . 
C QH^ON^O-QS Found Calculated 
(MW = 513) C 44.6 44.4 
4.5 
13.7 
4-Amino-6-methoxy-l- ( g-D-r ibofuranosyDpyrazolo [^'3, 4-df7 
pyrimidine (93) 
To a solution of 105 (0.3 g, 0.58 mmol) in abs.methanol 
(30 ml) was added MeONa (1 ml, 0.65 g Na in 12 ml abs.MeOH) 
and the mixture refluxed for 12 hrs. The resulting mixture 
was cooled, neutralized with AcOH and evaporated under reduced 
pressure. The brown residue, thus obtained, was subjected to 
c
H 
N 
.  
4 .6 
1 4 . 0 
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flash chromatography on SiO '{180 g) column. Elution with 
CHCl^-.MeOH (97.-3, v/v) gave £3 (yield, 0.14 g 80%), colour-
less granules (H2O). 
m.p. : 240 
MS: 297 (M"^ ) , 298 (M'^+I) 
UV (MeOH) : 285, 260 
IR(KBr): 3200-3500 (NH^ , OH) 
PMRlCDCl^+DMSO-dg): 8.50 (s, IH, H-3) , 7.25 (bs, 2H, NH2) / 
5.79 (d, IH, H-1', J = 4Hz), 3.8-3.12 (m, 6H, H-2', H-3', 
J. , ^  
H-4' i OH), 3.85 (s, 3H, OCH ), 3.60 (m, 2H, H-5') . 
C ,H N5O Found Calculated 
(MW = 297) C 44.5 44.4 
5.0 
23.6 
4-Amino-6-methylsulphonyl-l-(^D-ribofuranosyl)pyrazolo 
c 
H 
N 
4 4 . 5 
5.2 
23 .7 
r3,4-dl pyrimidine 
To a solution 91^  (0.5 g) in galcial acetic acid (8 ml) 
was added HO- (30%, 1.8 ml) and the mixture protected from 
light was kept at ambient temperature for 24 hrs. Ethanol 
(10 ml) added to it and evaporated. This was repeated four 
times. The final residue thus obtained was crystallized 
from H2O to give 106 (yield 0.17 g, 32%). 
m.p.: 259-60° (d) 
IR(KBr): 1220, 1340 (SO^CH^) 
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PMR (DMSO-dg): 8.01 (s, IH, H-3), 7.82 (bs, 2H, NH2), 6.15 
(d, IH, H-1', J^, 2.= 4Hz), 3.55 (s, 3H, SO2-CH3) . 
^11»15N5°6S 
(MW = 345) c 
H 
N 
Found 
38.6 
4.7 
20.1 
Ca l cu l a t ed 
38.3 
4 . 4 
20.3 
3.7 Biological Activity 
Antiviral assay; Ranikhet disease virus (RDV) was used for 
antiviral screening of the compounds. The strain of RDV, 
the haemagglutination test, the method of preparation of 
CAM culture, the optimal condition of the infection by the 
virus are described ~ . The stationary culture of chri-
allantoic membrane of 10 to 12 days old chick embryos were 
prepared from white leg horn eggs. 
Aqueous solution/suspension (0.1 mg/ml) of the compounds 
(92, 99_/ 9]^ / 1£1, 103_/ 104, 93_) were incubated to each CAM 
culture using 6 CAM culture sample along with 0.064 HA/ml 
of RDV. The cultures were incubated at 37° for 48 hrs. The 
percentage of inhibition of virus multiplication was assayed 
from the HA titre of the nutrient fluid of CAM culture infected 
with RDV. 
The compounds £2' il ^ nd SJ. exhibited 40, 50, 20% 
inhibition respectively and rest of the compound were found 
inactive. 
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